ANI Pharmaceuticals will announce Q3 2025 financial results on November 7, followed by a conference call.
Quiver AI Summary
ANI Pharmaceuticals, Inc. has announced it will release its financial results for the third quarter of 2025 on November 7, 2025, before the market opens. Following the release, a conference call will be held at 8:30 a.m. ET, featuring key executives including President and CEO Nikhil Lalwani. Participants can join the call by dialing the toll-free number provided or by streaming it live on the company's website, where a replay will also be available for two weeks. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing and marketing innovative therapeutics in various medical fields, including rare diseases. For more details, visit their website or contact their investor relations team.
Potential Positives
- Announcement of the upcoming third quarter financial results demonstrates transparency and accountability to investors.
- The involvement of key executives in the conference call signals strong leadership presence and commitment to stakeholder engagement.
- Focus on sustainable growth through diverse business segments, including Rare Diseases and Generics, indicates strategic planning and potential for future revenue streams.
- The company’s commitment to developing high-quality therapeutics reinforces its dedication to improving patient outcomes, aligning with positive public health contributions.
Potential Negatives
- None
FAQ
When will ANI Pharmaceuticals release its Q3 2025 financial results?
ANI Pharmaceuticals will release its third quarter 2025 financial results on Friday, November 7, 2025, prior to the market open.
Who will host the conference call for financial results?
Nikhil Lalwani, Stephen P. Carey, and Chris Mutz will host the conference call to discuss the financial results.
What time is the ANI Pharmaceuticals conference call scheduled for?
The conference call is scheduled for 8:30 a.m. ET on November 7, 2025.
How can I access the webcast of the conference call?
The webcast can be accessed live and for replay on the ANI Pharmaceuticals website under the “Investors” section.
When will the replay of the conference call be available?
A replay will be available within two hours of the call's completion and accessible for two weeks by phone.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANIP Insider Trading Activity
$ANIP insiders have traded $ANIP stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.
Here’s a breakdown of recent trading of $ANIP stock by insiders over the last 6 months:
- MUTHUSAMY SHANMUGAM (HEAD OF R&D, COO-NOVITIUM OPS) has made 0 purchases and 5 sales selling 200,700 shares for an estimated $17,914,322.
- NIKHIL LALWANI (PRESIDENT & CEO) sold 56,960 shares for an estimated $4,894,572
- STEPHEN P. CAREY (SVP & CFO) sold 50,000 shares for an estimated $4,303,500
- JEANNE THOMA has made 0 purchases and 2 sales selling 21,540 shares for an estimated $1,920,369.
- CHAD GASSERT (SVP - CORP. DEV. & STRATEGY) sold 20,000 shares for an estimated $1,739,400
- THOMAS HAUGHEY sold 19,341 shares for an estimated $1,661,972
- ANTONIO R PERA has made 0 purchases and 2 sales selling 12,713 shares for an estimated $1,178,728.
- MATTHEW J LEONARD has made 0 purchases and 2 sales selling 9,465 shares for an estimated $840,722.
- PATRICK D WALSH sold 9,000 shares for an estimated $801,450
- ORI GUTWERG (SVP, GENERICS) has made 0 purchases and 2 sales selling 6,754 shares for an estimated $561,112.
- THOMAS ANDREW ROWLAND (SVP, HEAD - ESTABLISHED BRANDS) sold 4,975 shares for an estimated $426,407
- KRISTA DAVIS (SVP, CHIEF HR OFFICER) has made 0 purchases and 2 sales selling 2,763 shares for an estimated $258,649.
- CHRISTOPHER MUTZ (HEAD OF RARE DISEASE) sold 4,000 shares for an estimated $241,800
- MEREDITH COOK (SR. VP, GENERAL COUNSEL & SEC.) has made 0 purchases and 6 sales selling 2,400 shares for an estimated $186,332.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANIP Hedge Fund Activity
We have seen 115 institutional investors add shares of $ANIP stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDMAN SACHS GROUP INC removed 426,166 shares (-67.5%) from their portfolio in Q2 2025, for an estimated $27,807,331
- NUVEEN, LLC added 322,375 shares (+663.3%) to their portfolio in Q2 2025, for an estimated $21,034,968
- MORGAN STANLEY removed 236,577 shares (-54.1%) from their portfolio in Q2 2025, for an estimated $15,436,649
- RUBRIC CAPITAL MANAGEMENT LP added 200,998 shares (+354.7%) to their portfolio in Q2 2025, for an estimated $13,115,119
- FREESTONE GROVE PARTNERS LP added 191,217 shares (+4784.0%) to their portfolio in Q2 2025, for an estimated $12,476,909
- MILLENNIUM MANAGEMENT LLC added 185,535 shares (+22.7%) to their portfolio in Q2 2025, for an estimated $12,106,158
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 173,941 shares (-77.4%) from their portfolio in Q2 2025, for an estimated $11,349,650
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANIP Analyst Ratings
Wall Street analysts have issued reports on $ANIP in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 09/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/17/2025
- Guggenheim issued a "Buy" rating on 09/08/2025
To track analyst ratings and price targets for $ANIP, check out Quiver Quantitative's $ANIP forecast page.
$ANIP Price Targets
Multiple analysts have issued price targets for $ANIP recently. We have seen 4 analysts offer price targets for $ANIP in the last 6 months, with a median target of $114.5.
Here are some recent targets:
- Gregory Fraser from Truist Securities set a target price of $90.0 on 10/09/2025
- Ekaterina Knyazkova from JP Morgan set a target price of $115.0 on 09/24/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $121.0 on 09/17/2025
- Vamil Divan from Guggenheim set a target price of $114.0 on 09/08/2025
Full Release
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results on Friday, November 7, 2025, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows:
| Date | Friday, November 7, 2025 |
| Time | 8:30 a.m. ET |
| Toll free (U.S.) | 800-267-6316 |
| Conference ID | 5120265 |
| Webcast (live and replay) | www.anipharmaceuticals.com , under the “Investors” section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-2391 and entering access code 5120265.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E:
[email protected]
